Drug Trial Radar · NCT06822907
Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,052
Planned (sponsor's estimate)
Start
Dec 17, 2025
Primary completion
Oct 1, 2028
Study completion Oct 1, 2028
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ministry of Health, France; IREIVAC/COVIREIVAC Network
- First posted
- Feb 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality. The incidence and therefore the burden of pneumococcal infections have been significantly reduced thanks to the use of pneumococcal conjugate vaccines (PCVs). PCVs were shown to be effective against vaccine-type serotypes causing both non-invasive and invasive pneumococcal diseases (IPD) in children and adults. PCVs use in children was shown to have an impact on IPD incidence among adults due to herd immunity and on antimicrobial resistance. To increase the protection of at-risk patients against IPD, the 20-valent PCV (PCV-20) is recently recommended in adults, after a period where PCV-13 followed by pneumococcal polysaccharide vaccine 23 valent (PPV-23) was recommended. PCV-20 effectiveness against IPD and against pneumonia was inferred from immunobridging with PCV-13. Indeed PCV-13 was shown effective to reduce the incidence of low respiratory tract infections and IPD (bacteraemia and meningitis) in 65-years-old-adults and older. Currently immunization against S. pneumoniae is recommended with PCV-20 for adult patients at-risk for IPD such as immunocompromised (=high-risk patients) and in immunocompetent people with underlying chronic conditions (cardiovascular, liver, pulmonary, kidney diseases and diabetes mellitus) (=medium risk patients). However, vaccine coverage against IPD in adults remains low globally, and does not exceed 5 % in France. Reducing missed opportunities of vaccination for S. pneumoniae is crucial.
Conditions
- Acute Febrile Illness
- Pneumococcal Infections
Interventions
Early interventionBiological
In this arm, patient will receive unique dose of the PCV-20 vaccine (Prevnar 20) as soon as possible and until 72h after apyrexia. The "Prevenar 20" will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults.
Delayed interventionBiological
In this arm, from 15 days and until 58 days after fever resolution (i.e after the first day with a body temperature \< 37.5°C without paracetamol use in the 6 previous hours) (whether or not the patient has been discharged) in the absence of fever, the patient will receive unique dose of the PCV-20 vaccine (Prevnar 20). The "Prevenar 20" will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of immune "good responders" to PCV-20 in both armsTime frame: 1 month post vaccination
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier
Annecy, France · Not yet recruiting
Centre Hospitalier Universitaire
Besançon, France · Not yet recruiting
Centre Hospitalier
Bordeaux, France · Not yet recruiting
Centre Hospitalier Universitaire
Brest, France · Not yet recruiting
Centre Hospitalier
Brest, France · Not yet recruiting
Centre Hospitalier General Metropole Savoie
Chambéry, France · Not yet recruiting
Centre Hospitalier de Creteil
Créteil, France · Not yet recruiting
Centre Hospitalier Universitaire
Dijon, France · Not yet recruiting
Centre Hospitalier Universitaire
Grenoble, France · Not yet recruiting
Centre Hospitalier
La Roche-sur-Yon, France · Not yet recruiting
Centre Hospitalier General
Le Mans, France · Not yet recruiting
Centre Hospitalier
Le Puy-en-Velay, France · Not yet recruiting
Centre Hospitalier Universitaire
Lille, France · Not yet recruiting
Hospices Civils de Lyon
Lyon, France · Not yet recruiting
Centre Hospitalier Regional Universitaire
Montpellier, France · Not yet recruiting
Centre Hospitalier Universitaire
Nancy, France · Not yet recruiting
Centre Hospitalier Universitaire
Nantes, France · Not yet recruiting
Centre Hospitalier Universitaire
Nice, France · Not yet recruiting
Centre Hospitalier Universitaire
Nîmes, France · Not yet recruiting
Centre Hospitalier Bichat
Paris, France · Not yet recruiting
Assistance Publique Hopitaux de Paris
Paris, France · Not yet recruiting
Centre Hospitalier Universitaire
Rennes, France · Not yet recruiting
Centre Hospitalier Universitaire
Rouen, France · Not yet recruiting
CHU de Saint-Etienne
Saint-Etienne, France, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.